TY - JOUR T1 - PrP concentration in the central nervous system: regional variability, genotypic effects, and pharmacodynamic impact JF - medRxiv DO - 10.1101/2021.11.01.21265619 SP - 2021.11.01.21265619 AU - Meredith A Mortberg AU - Hien T Zhao AU - Andrew G Reidenbach AU - Juliana E Gentile AU - Eric Kuhn AU - Jill O’Moore AU - Patrick M Dooley AU - Theresa R Connors AU - Curt Mazur AU - Shona W Allen AU - Bianca A Trombetta AU - Alison McManus AU - Matthew R Moore AU - Jiewu Liu AU - Deborah E Cabin AU - Holly B Kordasiewicz AU - Joel Mathews AU - Steven E Arnold AU - Sonia M Vallabh AU - Eric Vallabh Minikel Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/26/2021.11.01.21265619.abstract N2 - Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically and pharmacologically validated therapeutic target for prion disease. In order to evaluate PrP concentration as a pharmacodynamic biomarker and assess its contribution to known prion disease risk factors, we developed and validated a plate-based immunoassay reactive for PrP across six species of interest and applicable to brain and cerebrospinal fluid (CSF). PrP concentration varies dramatically between different brain regions in mice, cynomolgus macaques, and humans. PrP expression does not appear to contribute to the known risk factors of age, sex, or common PRNP genetic variants. CSF PrP is lowered in the presence of rare pathogenic PRNP variants, with heterozygous carriers of P102L displaying 55% and of D178N just 31% the CSF PrP concentration of mutation-negative controls. In rodents, pharmacologic reduction of brain Prnp RNA is reflected in brain parenchyma PrP, and in turn in CSF PrP, validating CSF as a sampling compartment for the effect of PrP-lowering therapy. Our findings support the use of CSF PrP as a pharmacodynamic biomarker for PrP-lowering drugs, and suggest that relative reduction from individual baseline CSF PrP concentration may be an appropriate marker for target engagement.Competing Interest StatementEVM has received consulting fees from Deerfield Management and has received research support in the form of unrestricted charitable contributions from Ionis Pharmaceuticals. SMV has received speaking fees from Ultragenyx, Illumina, and Biogen, and has received research support in the form of unrestricted charitable contributions from Ionis Pharmaceuticals. SEA has received honoraria and/or travel expenses for lectures from Abbvie, Biogen, EIP Pharma, Roche, and Sironax; has received fees for consulting and/or advisory boards from Athira, Biogen, Cassava, Cognito, Cortexyme, Sironax, and vTv; and has received grant support from Abbvie, Amylyx, EIP Pharma, Ionis Pharmaceuticals, and Merck. HTZ, CM, JM, and HBK are employees and shareholders of Ionis Pharmaceuticals. MRM is an employee of Bioagilytix. EK is an employee of Kymera. JL is currently an employee of Kriya Therapeutics. DEC has received grant support from Ionis Pharmaceuticals.Funding StatementThis study was funded by Prion Alliance, CJD Foundation (the Michael H. Cole, Cheryl Molloy, Jose A. Piriz and Sonia E. Piriz, Jeffrey A. Smith, and Mercies in Disguise Memorial Grants), Ionis Pharmaceuticals (internal efforts and support to DEC), the Broad Institute (including direct philanthropic donations to Prions@Broad), the National Institutes of Health (R21 TR003040 to SEA), Ono Pharma Foundation, and an anonymous organization.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Partners Healthcare IRB gave ethical approval for this work (protocol #2017P000214).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data and source code sufficient to reproduce the figures and analyses herein are available in the online git repository of this study with the exception of sensitive patient data, which are available upon reasonable request to the authors. https://github.com/ericminikel/cns_prp_quant ER -